Bluefish gets approval for six new pharmaceuticals

Bluefish Pharmaceuticals has expanded its product portfolio with six new approved pharmaceuticals in the past quarter. A number of European medical product authorities have granted approval for products pertaining to therapy for the central nervous system, cardiovascular disease, and stomach/bowel (proton pump inhibitors). The approved pharmaceutical substances are Gabapentin, Sertraline, Sumatriptan, Risperidon, Losartan and Lansoprazol. Sales for these pharmaceuticals total SEK 19.5 billion per year in the EU.

“These new approvals attest to the quality of the company’s product portfolio, and the high competence that exists within the Bluefish regulatory unit. This also makes it possible to begin selling a greater number of products in 2008,” says Bluefish President and CEO Karl Karlsson.
Bluefish currently has twelve approved pharmaceuticals and another nine under registration in the EU.
Bluefish pharmaceuticals are manufactured in India, where the company has a wholly-owned subsidiary.

For more information, please contact: Karl Karlsson, President and CEO,
+ 46 8 679 50 70

Bluefish Pharmaceuticals AB is a Swedish pharmaceutical company that licenses, develops, manufactures and markets mainly generic pharmaceutical products. Low prices are maintained through efficient production and distribution. Bluefish has a wholly owned subsidiary in Chennai, India, focusing on product development and production. The company is owned by its founder Karl Karlsson, together with a number of investment funds and private investors.